These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19766755)

  • 21. [New methods in insulin treatment].
    Neuwirth G
    Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
    Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
    Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
    Home PD; Fritsche A; Schinzel S; Massi-Benedetti M
    Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.
    Kostev K; Dippel FW; Rockel T; Siegmund T
    J Wound Care; 2012 Oct; 21(10):483-4, 486-9. PubMed ID: 23103482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes.
    Lipska KJ; Wang Y; Kosiborod M; Masoudi FA; Havranek EP; Krumholz HM; Inzucchi SE
    Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):236-42. PubMed ID: 20354220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin].
    Hu M; Luo Y; Zhang L; Yang X; Zhang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Jun; 27(3):622-5. PubMed ID: 20649032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
    Buysman E; Conner C; Aagren M; Bouchard J; Liu F
    Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.
    Rhoads GG; Dain MP; Zhang Q; Kennedy L
    Diabetes Obes Metab; 2011 Aug; 13(8):711-7. PubMed ID: 21410859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
    Valentine WJ; Aagren M; Haglund M; Ericsson A; Gschwend MH
    Scand J Public Health; 2011 Feb; 39(1):79-87. PubMed ID: 20688795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study.
    Negrato CA; Rafacho A; Negrato G; Teixeira MF; Araújo CA; Vieira L; Silva CA; Date SK; Demarchi AC; Gomes MB
    Diabetes Res Clin Pract; 2010 Jul; 89(1):46-51. PubMed ID: 20378197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.
    Christensen TE; Gundgaard J; Pilgaard T
    J Med Econ; 2011; 14(4):477-85. PubMed ID: 21668290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of ten-year event-free survival in patients with acute myocardial infarction (from the Adria, Bassano, Conegliano, and Padova Hospitals [ABC] study on myocardial infarction).
    Berton G; Cordiano R; Cavuto F; Giacomini G; De Toni R; Palatini P
    Am J Cardiol; 2012 Apr; 109(7):966-75. PubMed ID: 22221943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
    J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.